{"id":"NCT02793128","sponsor":"UroGen Pharma Ltd.","briefTitle":"The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study","officialTitle":"A Phase 3 Multicenter Trial Evaluating the Efficacy and Safety of UGN-101 on Ablation of Upper Urinary Tract Urothelial Carcinoma","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-04-04","primaryCompletion":"2019-04-05","completion":"2020-03-05","firstPosted":"2016-06-08","resultsPosted":"2020-11-20","lastUpdate":"2020-12-22"},"enrollment":71,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Carcinoma, Transitional Cell","Transitional Cell Carcinoma of Renal Pelvis"],"interventions":[{"type":"DRUG","name":"UGN-101 instillations","otherNames":["UGN-101"]}],"arms":[{"label":"UGN-101 instillations","type":"EXPERIMENTAL"}],"summary":"The study is investigating the ability of UroGen's UGN-101 to treat urothelial carcinoma tumors from the upper urinary tract.","primaryOutcome":{"measure":"The Primary Efficacy Endpoint Was the Number of Patients Attaining Complete Response (CR) at the End of the Treatment Period (PDE Visit).","timeFrame":"An average of 11 weeks","effectByArm":[{"arm":"UGN-101 Mitomycin for Pyelocalyceal Solution","deltaMin":42,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":24,"countries":["United States","Israel"]},"refs":{"pmids":["39561384","33677615","32670424","32631491"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":28,"n":71},"commonTop":["Ureteric stenosis","Urinary tract infection","Haematuria","Flank Pain","Nausea"]}}